文献速递造血干细胞移植与细胞治疗

新型RIPK1抑制剂通过恢复肠道稳态的非免疫抑制机制减轻小鼠GVHD

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis.
PubMed 文献 · Blood · 2023-01-01

该研究报道肠上皮细胞(IEC)依赖受体相互作用蛋白激酶3(RIPK3)驱动异基因造血干细胞移植后的胃肠道及全身性移植物抗宿主病(GVHD),IEC中RIPK3与RIPK1协同触发不依赖混合谱系激酶结构域样蛋白的T细胞招募趋化因子及MHC II类分子产生,放大并维持同种反应性T细胞应答。严重GVHD患者结肠上皮显示高度活化的RIPK1。选择性RIPK1抑制剂Zharp1-211可显著减少IEC中JAK/STAT1介导的趋化因子和MHC II类分子表达,恢复肠道稳态并阻止GVHD而不损害移植物抗白血病(GVL)效应。

要点

  • IEC中RIPK3驱动异基因造血干细胞移植后胃肠道和全身性GVHD。
  • RIPK1/RIPK3与JAK1形成复合物促进IEC中STAT1活化,形成正反馈炎症级联。
  • RIPK1抑制剂Zharp1-211恢复肠道稳态、阻止GVHD且不损害GVL效应。

核心结论

  • 靶向IEC中的RIPK1/RIPK3是一种有效的非免疫抑制策略,可用于GVHD治疗并可能用于其他涉及胃肠道炎症的疾病。

研究设计与样本

  • 小鼠异基因造血干细胞移植模型研究,并检测严重GVHD患者结肠上皮。

主要发现

  • IEC选择性抑制RIPK3显著减轻小鼠肠道和肝脏GVHD。
  • IEC中RIPK1/RIPK3协同触发不依赖MLKL的T细胞招募趋化因子及MHC II类分子产生,放大并维持同种反应性T细胞应答。
  • 同种反应性T细胞产生的干扰素γ通过JAK/STAT1依赖机制增强IEC中RIPK1/RIPK3作用,形成正反馈炎症级联。
  • RIPK1/RIPK3与JAK1形成复合物促进IEC中STAT1活化。
  • 严重GVHD患者结肠上皮显示高度活化的RIPK1。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intestinal epithelial cells (IECs) are implicated in the propagation of T-cell-mediated inflammatory diseases, including graft-versus-host disease (GVHD), but the underlying mechanism remains poorly defined. Here, we report that IECs require receptor-interacting protein kinase-3 (RIPK3) to drive both gastrointestinal (GI) tract and systemic GVHD after allogeneic hematopoietic stem cell transplantation. Selectively inhibiting RIPK3 in IECs markedly reduces GVHD in murine intestine and liver. IEC RIPK3 cooperates with RIPK1 to trigger mixed lineage kinase domain-like protein-independent production of T-cell-recruiting chemokines and major histocompatibility complex (MHC) class II molecules, which amplify and sustain alloreactive T-cell responses. Alloreactive T-cell-produced interferon gamma enhances this RIPK1/RIPK3 action in IECs through a JAK/STAT1-dependent mechanism, creating a feed-forward inflammatory cascade. RIPK1/RIPK3 forms a complex with JAK1 to promote STAT1 activation in IECs. The RIPK1/RIPK3-mediated inflammatory cascade of alloreactive T-cell responses results in intestinal tissue damage, converting the local inflammation into a systemic syndrome. Human patients with severe GVHD showed highly activated RIPK1 in the colon epithelium. Finally, we discover a selective and potent RIPK1 inhibitor (Zharp1-211) that significantly reduces JAK/STAT1-mediated expression of chemokines and MHC class II molecules in IECs, restores intestinal homeostasis, and arrests GVHD without compromising the graft-versus-leukemia (GVL) effect. Thus, targeting RIPK1/RIPK3 in IECs represents an effective nonimmunosuppressive strategy for GVHD treatment and potentially for other diseases involving GI tract inflammation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yu X, Ma H, Li B, et al. A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis. Blood. 2023. PMID: 36356302. doi:10.1182/blood.2022017262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。